Who are SPD503 (Guanfacine HCl)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lucemyra, Neurontin, Iopidine, Dipivefrin, Sudafed, Catapres-Tts-1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/spd503-guanfacine-hcl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

SPD503 (Guanfacine HCl) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SPD503 (Guanfacine HCl) (SPD503 (Guanfacine HCl)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2A adrenergic receptor agonist. Area: Neurology / Psychiatry.

phase 3 Alpha-2A adrenergic receptor agonist Alpha-2A adrenergic receptor Neurology / Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

SPD503 (Guanfacine HCl) (SPD503 (Guanfacine HCl)) — Shire. Guanfacine is an alpha-2A adrenergic receptor agonist that reduces norepinephrine activity in the prefrontal cortex to improve attention and impulse control.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SPD503 (Guanfacine HCl) TARGET	SPD503 (Guanfacine HCl)	Shire	phase 3	Alpha-2A adrenergic receptor agonist	Alpha-2A adrenergic receptor
Lucemyra	LOFEXIDINE	Biocorrx Pharms	marketed	lofexidine	Alpha-2A adrenergic receptor	2018-01-01
Neurontin	gabapentin	Generic (originally Parke-Davis/Pfizer)	marketed	Gabapentinoid (anticonvulsant/neuropathic pain agent)	Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor	1993-12-30
Iopidine	APRACLONIDINE	Harrow Health	marketed	alpha-Adrenergic Agonist	Alpha-2A adrenergic receptor	1987-01-01
Dipivefrin	dipivefrine	AbbVie	marketed	Adrenergic Receptor Agonist	Alpha-2A adrenergic receptor	1980-01-01
Sudafed	pseudoephedrine	Generic (multiple manufacturers)	marketed	Nasal decongestant (sympathomimetic)	Alpha-1A adrenergic receptor, Alpha-2A adrenergic receptor, Beta-2 adrenergic receptor	1976-01-01
Catapres-Tts-1	CLONIDINE	Lavipharm	marketed	Central alpha-2 Adrenergic Agonist	Alpha-2A adrenergic receptor	1974-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-04-17 — Catapres-Tts-1 · 8337890 · Formulation · US
2031-09-08 — Catapres-Tts-1 · 8623409 · Formulation · US

Sponsor landscape (Alpha-2A adrenergic receptor agonist class)

Children's Hospital Medical Center, Cincinnati · 1 drug in this class
Neurology Group of Bergen County, P.A. · 1 drug in this class
Research Foundation for Mental Hygiene, Inc. · 1 drug in this class
Shire · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SPD503 (Guanfacine HCl) — Competitive Intelligence Brief. https://druglandscape.com/ci/spd503-guanfacine-hcl. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab